Steglujan Patent Expiration

Steglujan is a drug owned by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc. It is protected by 10 US drug patents filed from 2018 to 2021. Out of these, 5 drug patents are active and 5 have expired. Steglujan's patents have been open to challenges since 19 December, 2021. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 21, 2030. Details of Steglujan's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US8080580 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(5 years from now)

Active
US7326708 Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(1 year, 11 months from now)

Active
US6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(2 years ago)

Expired
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9439901 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(5 years from now)

Active
US9308204 Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(5 years from now)

Active
US7326708

(Pediatric)

Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(2 years from now)

Active
US6699871

(Pediatric)

Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(1 year, 10 months ago)

Expired
US6890898 Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

Expired
US7078381 Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

Expired
US7459428 Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Steglujan's patents.

Given below is the list of recent legal activities going on the following patents of Steglujan.

Activity Date Patent Number
Patent litigations
transaction for FDA Determination of Regulatory Review Period 27 Jun, 2024 US8080580
Payment of Maintenance Fee, 12th Year, Large Entity 10 May, 2023 US8080580
Second letter to regulating agency to determine regulatory review period 22 Apr, 2021 US8080580
Second letter to regulating agency to determine regulatory review period 15 Apr, 2021 US8080580
Letter from FDA or Dept of Agriculture re PTE application 12 Jun, 2019 US8080580
Payment of Maintenance Fee, 8th Year, Large Entity 14 May, 2019 US8080580
Initial letter Re: PTE Application to regulating agency 15 Oct, 2018 US8080580
Patent Term Extension Application under 35 USC 156 Filed 15 Feb, 2018 US8080580
Recordation of Patent Grant Mailed 20 Dec, 2011 US8080580
Patent Issue Date Used in PTA Calculation 20 Dec, 2011 US8080580


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Steglujan and ongoing litigations to help you estimate the early arrival of Steglujan generic.

Steglujan's Litigations

Steglujan been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 10, 2020, against patent number US7326708. The petitioner Teva Pharmaceuticals USA, Inc., challenged the validity of this patent, with Merck Sharp & Dohme Corp. as the respondent. Click below to track the latest information on how companies are challenging Steglujan's patents.

Last updated on December 10, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7326708 June, 2020 Final Written Decision
(10 May, 2021)
Merck Sharp & Dohme Corp. et al. Dr. Reddy's Laboratories, Inc. et al.
US7326708 June, 2020 Final Written Decision
(10 May, 2021)
Merck Sharp & Dohme Corp. et al. Sun Pharmaceutical Industries Ltd. et al.
US7326708 October, 2019 Final Written Decision
(07 May, 2021)
Merck Sharp & Dohme Corp. et al. Mylan Pharmaceuticals, Inc.
US7326708 June, 2020 Terminated-Settled
(08 Dec, 2020)
Merck Sharp & Dohme Corp. Teva Pharmaceuticals USA, Inc.


FDA has granted some exclusivities to Steglujan. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Steglujan, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Steglujan.

Exclusivity Information

Steglujan holds 2 exclusivities. All of its exclusivities have expired in 2024. Details of Steglujan's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 19, 2022
M(M-275) Sep 17, 2024

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Steglujan's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Steglujan's generic, the next section provides detailed information on ongoing and past EP oppositions related to Steglujan patents.

Steglujan's Oppositions Filed in EPO

Steglujan has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jun 11, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04755691A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP05077584A Mar, 2011 APOTEX INC. Revoked
EP04755691A Jun, 2008 Teva Pharmaceutical Industries Ltd. Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Steglujan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Steglujan's family patents as well as insights into ongoing legal events on those patents.

Steglujan's Family Patents

Steglujan has patent protection in a total of 56 countries. It's US patent count contributes only to 13.0% of its total global patent coverage. 11 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Steglujan.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Steglujan's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 21, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Steglujan Generics:

There are no approved generic versions for Steglujan as of now.

Alternative Brands for Steglujan

Steglujan which is used for improving glycemic control in adults with type 2 diabetes., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Msd Sub Merck
Steglatro used for improving glycemic control in adults with type 2 diabetes.
Segluromet Used for improving glycemic control in adults with type 2 diabetes.
Theracosbio
Brenzavvy Used for improving glycemic control in adults with type 2 diabetes.





About Steglujan

Steglujan is a drug owned by Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc. It is used for improving glycemic control in adults with type 2 diabetes. Steglujan uses Ertugliflozin; Sitagliptin Phosphate as an active ingredient. Steglujan was launched by Msd Sub Merck in 2017.

Approval Date:

Steglujan was approved by FDA for market use on 19 December, 2017.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Steglujan is 19 December, 2017, its NCE-1 date is estimated to be 19 December, 2021.

Active Ingredient:

Steglujan uses Ertugliflozin; Sitagliptin Phosphate as the active ingredient. Check out other Drugs and Companies using Ertugliflozin; Sitagliptin Phosphate ingredient

Treatment:

Steglujan is used for improving glycemic control in adults with type 2 diabetes.

Dosage:

Steglujan is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
15MG;EQ 100MG BASE TABLET Prescription ORAL
5MG;EQ 100MG BASE TABLET Prescription ORAL